Intravenous infusion therapy has become critical for the treatment and maintenance of many pediatric rheumatic diseases, such as juvenile idiopathic arthritis, systemic lupus erythematosus, and inflammatory bowel disease-associated arthritis. Recently, researchers conducted a retrospective review of all pediatric patients given infusions at the University of Alabama at Birmingham from 2012 to 2015.
Intravenous infusion therapy has become critical for the treatment and maintenance of many pediatric rheumatic diseases, such as juvenile idiopathic arthritis, systemic lupus erythematosus, and inflammatory bowel disease-associated arthritis. Recently, researchers conducted a retrospective review of all pediatric patients given infusions at the University of Alabama at Birmingham (UAB) from 2012 to 2015.
The Pediatric Rheumatology Infusion Center at UAB infuses the following medications: abatacept, belimumab, cyclophosphamide, immune globulin, infliximab, methylprednisolone, n-acetylcysteine, pamidronate disodium, rituximab, and tocilizumab. Data for the study were collected directly from the electronic medical records of the center's patients. For the year 2015, a manual search of each infusion was performed to identify any adverse events (AEs) that occurred during the infusions, as well as management of the reactions. Safety events that occurred outside the context of infusions (such as infections) were not included in this report.
From 2012 to 2015, 7585 intravenous infusions were administered to 398 unique patients for both on-label and off-label indications. In 2015 alone, 2187 infusions were administered to 224 patients, with 34 patients experiencing 41 infusion-related reactions (1.9%). The most common infusion reactions were nausea and vomiting and throat discomfort.
Medications that led to infusion-related reactions were abatacept, infliximab, immune globulin, methylprednisolone, rituximab, and tocilizumab. Rituximab had the highest rate of AEs, with 10 patients experiencing reactions during 106 infusions (9.4%). Across all drug and AEs, none of the reactions were life-threatening, and only 6 resulted in discontinuation of therapy (3 for infliximab, 2 for methylprednisolone, and 1 for rituximab rituximab).
Conversely, belimumab, cyclophosphamide, and pamidronate did not result in any AEs.
The adverse reactions were treated with either non-steroidal anti-inflammatory drugs, diphenhydramine, or intravenous fluids. Per protocol, if the symptoms were deemed non-life threatening and resolved with additional conservative therapies, re-starting of the infusion was permitted.
Overall, the study found that the AEs associated with these infusions were mild and resolved after using protocol-derived management strategies. Through the combination of standardized infusion protocols, the experience of physician and nurses administering the treatments, and the safety profile of the medication itself, the study found that intravenous infusions for pediatric patients can safely be administered.
Reference
Vinod S, Reed A, Maxwell J, Cron R, Stoll M. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 years with focus on adverse events over 1 year. Published online March 9, 2018. Pediatr Rheumatol Online J. doi: 10.1186/s12969-018-0234-0.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.